Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Drug review

- PMLiVE

Infographic: Are data blind spots putting your launch at risk?

Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize...

Inizio

- PMLiVE

Real Chemistry Launches Real Chemistry ANATOMI, an AI Ecosystem Purpose-Built for Healthcare Commercialization

The unique combination of technology marks 25 years of industry innovation and expertise, and signals company’s next phase of business growth and client value

Real Chemistry

- PMLiVE

Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA

Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma

- PMLiVE

Teva submits FDA application for paediatric Tourette syndrome therapy

Ecopipam could become the first new FDA-approved treatment for paediatric Tourette syndrome in over ten years

- PMLiVE

Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment

This is the first and only at-home subcutaneous treatment option for this disease

- PMLiVE

Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026

Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it...

Genesis Research Group

- PMLiVE

Regeneron’s New Drug Application for cemdisiran accepted for review by FDA and EMA

Globally, around 150 to 200 out of every million people have myasthenia gravis

- PMLiVE

Healthcare information is becoming easier to access. Trust isn’t.

Sharing key insights from NEXT Pharma Summit on why trust, clarity and human-centred communication matter more than ever in healthcare.

Cuttsy + Cuttsy

- PMLiVE

Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer

Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years

- PMLiVE

Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis

This new option for patients allows for as few as six maintenance injections per year

- PMLiVE

Medscape Education Brings AI to the Hematology Frontline at EHA 2026

Medscape Education is supporting a dedicated AI symposium at the 2026 European Hematology Association (EHA) Annual Congress in Stockholm on June 11, 2026.

Medscape Education

- PMLiVE

Bristol Myers Squibb announces strategic agreement with Anthropic

The collaboration builds on more than three years of AI investment by the company

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links